View Post

First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

In Clinical Studies News by Barbara Jacoby

From: Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial). The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer. The trial …